Literature DB >> 29074008

Risk factors for progression of diabetic retinopathy in Alberta First Nations communities.

Christopher J Rudnisky1, Beatrice K Wong2, Hakique Virani3, Matthew T S Tennant4.   

Abstract

OBJECTIVE: The Screening for Limb, I-Eye, Cardiovascular, and Kidney Complications (SLICK) Program was implemented in 1999 to improve diabetic care for Alberta First Nations individuals living on reserve. The purpose of this review is to determine the rate and predictors of progression of diabetic retinopathy (DR) over a 10-year period.
DESIGN: Cohort study. PARTICIPANTS: Nine hundred and eighty First Nations patients with diabetes that underwent at least 2 teleophthalmology examinations during the study period.
METHODS: Patients underwent serial laboratory testing, and stereoscopic, mydriatic, retinal photography. Modified Early Treatment Diabetic Retinopathy Study grading of retinal images was performed via teleophthalmology. Progression was defined as an increase of 2 or more steps on the Diabetes Control and Complications Trial classification.
RESULTS: At baseline, most patients had no diabetic retinopathy (n = 777, 79.3%) whereas 203 people (20.7%) had either nonproliferative DR (n = 179, 18.3%) or proliferative DR (n = 24, 2.5%). Two-step progression occurred in 163 patients (16.6%), with only a minority of these individuals progressing to proliferative DR (n = 23). The median time to progression was 7.6 years. Multivariate Cox regression demonstrated that elevated hemoglobin A1C (hazard ratio [HR] = 1.42; p < 0.0001) and systolic blood pressure (HR = 1.24 per 10 mm Hg; p = 0.009) were independent predictors of progression of DR.
CONCLUSIONS: This population-based study has shown that the rate and predictors of progression of DR among First Nations individuals parallels non-First Nations populations, with HbA1C and systolic blood pressure being the strongest predictors. These findings suggest that targeted, individualized care to reduce blood pressure and control blood sugars could reduce progression of diabetic retinopathy, and possibly blindness in First Nations individuals living on reserve.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29074008     DOI: 10.1016/j.jcjo.2017.09.023

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  6 in total

1.  Diabetes-induced eye disease among First Nations people in Ontario: a longitudinal, population-based cohort study.

Authors:  Robert J Campbell; Roseanne Sutherland; Shahriar Khan; Katharine M Doliszny; Philip L Hooper; Morgan Slater; Eliot Frymire; Baiju R Shah; Jennifer D Walker; Michael E Green
Journal:  CMAJ Open       Date:  2020-04-17

2.  Association Between Increased Lipid Profiles and Risk of Diabetic Retinopathy in a Population-Based Case-Control Study.

Authors:  Zhenzhen Liu; Mingxi Shao; Jun Ren; Yichao Qiu; Shengjie Li; Wenjun Cao
Journal:  J Inflamm Res       Date:  2022-06-10

3.  Assessing Eye Health and Eye Care Needs Among North American Native Individuals.

Authors:  Maria A Woodward; Kathleen Hughes; Dena Ballouz; Richard A Hirth; Josh Errickson; Paula Anne Newman-Casey
Journal:  JAMA Ophthalmol       Date:  2022-02-01       Impact factor: 7.389

4.  Early Screening for Diabetic Retinopathy in Newly Diagnosed Type 2 Diabetes and Its Effectiveness in Terms of Morbidity and Clinical Treatment: A Nationwide Population-Based Cohort.

Authors:  Yu-Chien Chung; Ting Xu; Tao-Hsin Tung; Mingchih Chen; Pei-En Chen
Journal:  Front Public Health       Date:  2022-04-26

5.  Combined effect of glycemic and blood pressure control on diabetic retinopathy among Chinese with type-2 diabetes mellitus.

Authors:  Chen-Wei Pan; Shan Wang; Cai-Lian Xu; E Song
Journal:  Diabetol Metab Syndr       Date:  2018-10-01       Impact factor: 3.320

6.  Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.

Authors:  Yoo-Ri Chung; Kyoung Hwa Ha; Kihwang Lee; Dae Jung Kim
Journal:  PLoS One       Date:  2019-10-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.